IL6 and COVID-19: It has been shown that the antimalarial drug hydroxychloroquine (Plaquenil) inhibits the expression of toll-like receptors (TLRs) and the production of IL-6, and hence may have an anti-COVID-19 impact (Wang et al., 2020).